<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIPYRIDAMOLE</span><br/>(dye-peer-id'a-mole)<br/><span class="topboxtradename">Apo-Dipyridamole <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Persantine, </span><span class="topboxtradename">Pyridamole, </span><span class="topboxtradename">IV Persantine<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antiplatelet agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 75 mg tablets; 10 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Nonnitrate coronary vasodilator with many properties similar to those of papaverine.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases coronary blood flow by selectively dilating coronary arteries, thereby increasing myocardial oxygen supply. Exhibits
         mild inotropic action. Also has antiplatelet activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To prevent postoperative thromboembolic complications associated with prosthetic heart valves and as adjunct for thallium
         stress testing.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To reduce rate of reinfarction following MI; to prevent TIAs (transient ischemic attacks) and coronary bypass graft occlusion.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypotension, anticoagulant therapy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of Thromboembolism in Cardiac Valve Replacement</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75100 mg q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 12 mg t.i.d.<br/><br/><span class="indicationtitle">Thromboembolic Disorders</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150400 mg/d in divided doses<br/><br/><span class="indicationtitle">Thallium Stress Test</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.142 mg/kg/min for 4 min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach at least 1 h before or 2 h after meals, with a full glass of water. Physician may prescribe with
            food if gastric distress persists.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute to at least a 1:2 ratio with 0.45% NaCl, NS, or D5W to yield a final volume of 2050 mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 4 min (0.142 mg kg/min).  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store in tightly closed container at 15°30° C (59°86° F) unless otherwise directed. Protect
            injection from direct light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1> Usually dose related, minimal, and transient. <span class="typehead">CNS:</span> Headache, dizziness, faintness, syncope, weakness. <span class="typehead">CV:</span> Peripheral vasodilation, flushing. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, abdominal distress. <span class="typehead">Skin:</span> Skin rash, pruritus. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 45150 min. <span class="typehead">Distribution:</span> Small amount crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Mainly excreted in feces. <span class="typehead">Half-Life:</span> 1012 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. Clinical response may not be evident before second or third month of continuous therapy.
            Effects include reduced frequency or elimination of anginal episodes, improved exercise tolerance, reduced requirement for
            nitrates.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of any adverse effects.</li>
<li>Make all position changes slowly and in stages, especially from recumbent to upright posture, if postural hypotension or dizziness
            is a problem.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>